FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003453345> ?p ?o ?g. }

• W2003453345 endingPage "796" @default.
• W2003453345 startingPage "787" @default.
• W2003453345 abstract "Multiple lines of evidence have validated the Rho pathway as important in controlling the neuronal response to growth inhibitory proteins after central nervous system (CNS) injury. A drug called BA-210 (trademarked as Cethrin®) blocks activation of Rho and has shown promise in pre-clinical animal studies in being used to treat spinal cord injury (SCI). This is a report of a Phase I/IIa clinical study designed to test the safety and tolerability of the drug, and the neurological status of patients following the administration of a single dose of BA-210 applied during surgery following acute SCI. Patients with thoracic (T2-T12) or cervical (C4-T1) SCI were sequentially recruited for this dose-ranging (0.3 mg to 9 mg Cethrin), multi-center study of 48 patients with complete American Spinal Injury Association assessment (ASIA) A. Vital signs; clinical laboratory tests; computed tomography (CT) scans of the spine, head, and abdomen; magnetic resonance imaging (MRI) of the spine, and ASIA assessment were performed in the pre-study period and in follow-up periods out to 1 year after treatment. The treatment-emergent adverse events that were reported were typical for a population of acute SCI patients, and no serious adverse events were attributed to the drug. The pharmacokinetic analysis showed low levels of systemic exposure to the drug, and there was high inter-patient variability. Changes in ASIA motor scores from baseline were low across all dose groups in thoracic patients (1.8±5.1) and larger in cervical patients (18.6±19.3). The largest change in motor score was observed in the cervical patients treated with 3 mg of Cethrin in whom a 27.3±13.3 point improvement in ASIA motor score at 12 months was observed. Approximately 6% of thoracic patients converted from ASIA A to ASIA C or D compared to 31% of cervical patients and 66% for the 3-mg cervical cohort. Although the patient numbers are small, the observed motor recovery in this open-label trial suggests that BA-210 may increase neurological recovery after complete SCI. Further clinical trials with Cethrin in SCI patients are planned, to establish evidence of efficacy." @default.
• W2003453345 created "2016-06-24" @default.
• W2003453345 creator A5004189636 @default.
• W2003453345 creator A5011321296 @default.
• W2003453345 creator A5019085467 @default.
• W2003453345 creator A5024927085 @default.
• W2003453345 creator A5027259098 @default.
• W2003453345 creator A5035898051 @default.
• W2003453345 creator A5044959686 @default.
• W2003453345 creator A5047977949 @default.
• W2003453345 creator A5051781253 @default.
• W2003453345 creator A5054749088 @default.
• W2003453345 creator A5091308743 @default.
• W2003453345 date "2011-05-01" @default.
• W2003453345 modified "2023-10-16" @default.
• W2003453345 title "A Phase I/IIa Clinical Trial of a Recombinant Rho Protein Antagonist in Acute Spinal Cord Injury" @default.
• W2003453345 cites W1595029695 @default.
• W2003453345 cites W1983712592 @default.
• W2003453345 cites W1985829219 @default.
• W2003453345 cites W1989493703 @default.
• W2003453345 cites W2010378000 @default.
• W2003453345 cites W2012924135 @default.
• W2003453345 cites W2013035816 @default.
• W2003453345 cites W2020122922 @default.
• W2003453345 cites W2022369108 @default.
• W2003453345 cites W2031418398 @default.
• W2003453345 cites W2035120744 @default.
• W2003453345 cites W2037953829 @default.
• W2003453345 cites W2053556184 @default.
• W2003453345 cites W2071663291 @default.
• W2003453345 cites W2084733055 @default.
• W2003453345 cites W2095924978 @default.
• W2003453345 cites W2097325660 @default.
• W2003453345 cites W2099359509 @default.
• W2003453345 cites W2104907082 @default.
• W2003453345 cites W2124308710 @default.
• W2003453345 cites W2128457464 @default.
• W2003453345 cites W2141735603 @default.
• W2003453345 cites W2149942972 @default.
• W2003453345 cites W2166125615 @default.
• W2003453345 cites W2178562205 @default.
• W2003453345 cites W2316255286 @default.
• W2003453345 cites W70672885 @default.
• W2003453345 doi "https://doi.org/10.1089/neu.2011.1765" @default.
• W2003453345 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21381984" @default.
• W2003453345 hasPublicationYear "2011" @default.
• W2003453345 type Work @default.
• W2003453345 sameAs 2003453345 @default.
• W2003453345 citedByCount "222" @default.
• W2003453345 countsByYear W20034533452012 @default.
• W2003453345 countsByYear W20034533452013 @default.
• W2003453345 countsByYear W20034533452014 @default.
• W2003453345 countsByYear W20034533452015 @default.
• W2003453345 countsByYear W20034533452016 @default.
• W2003453345 countsByYear W20034533452017 @default.
• W2003453345 countsByYear W20034533452018 @default.
• W2003453345 countsByYear W20034533452019 @default.
• W2003453345 countsByYear W20034533452020 @default.
• W2003453345 countsByYear W20034533452021 @default.
• W2003453345 countsByYear W20034533452022 @default.
• W2003453345 countsByYear W20034533452023 @default.
• W2003453345 crossrefType "journal-article" @default.
• W2003453345 hasAuthorship W2003453345A5004189636 @default.
• W2003453345 hasAuthorship W2003453345A5011321296 @default.
• W2003453345 hasAuthorship W2003453345A5019085467 @default.
• W2003453345 hasAuthorship W2003453345A5024927085 @default.
• W2003453345 hasAuthorship W2003453345A5027259098 @default.
• W2003453345 hasAuthorship W2003453345A5035898051 @default.
• W2003453345 hasAuthorship W2003453345A5044959686 @default.
• W2003453345 hasAuthorship W2003453345A5047977949 @default.
• W2003453345 hasAuthorship W2003453345A5051781253 @default.
• W2003453345 hasAuthorship W2003453345A5054749088 @default.
• W2003453345 hasAuthorship W2003453345A5091308743 @default.
• W2003453345 hasBestOaLocation W20034533452 @default.
• W2003453345 hasConcept C118552586 @default.
• W2003453345 hasConcept C126322002 @default.
• W2003453345 hasConcept C126838900 @default.
• W2003453345 hasConcept C143409427 @default.
• W2003453345 hasConcept C197934379 @default.
• W2003453345 hasConcept C2778231337 @default.
• W2003453345 hasConcept C2778334475 @default.
• W2003453345 hasConcept C2778375690 @default.
• W2003453345 hasConcept C2780775167 @default.
• W2003453345 hasConcept C2908647359 @default.
• W2003453345 hasConcept C42219234 @default.
• W2003453345 hasConcept C535046627 @default.
• W2003453345 hasConcept C71924100 @default.
• W2003453345 hasConcept C99454951 @default.
• W2003453345 hasConceptScore W2003453345C118552586 @default.
• W2003453345 hasConceptScore W2003453345C126322002 @default.
• W2003453345 hasConceptScore W2003453345C126838900 @default.
• W2003453345 hasConceptScore W2003453345C143409427 @default.
• W2003453345 hasConceptScore W2003453345C197934379 @default.
• W2003453345 hasConceptScore W2003453345C2778231337 @default.
• W2003453345 hasConceptScore W2003453345C2778334475 @default.
• W2003453345 hasConceptScore W2003453345C2778375690 @default.
• W2003453345 hasConceptScore W2003453345C2780775167 @default.
• W2003453345 hasConceptScore W2003453345C2908647359 @default.

• next